Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
← catalyst calendarNCT04262466 · readout ≤ 73 d
Sponsored by Immunocore Ltd (industry) · IMCR — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
410actual
Sites
76
Countries
Australia, Austria, Belgium +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-02-25 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2020-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Select Advanced Solid Tumors
Interventions
- Drug: Brenetafusp
- Drug: Brenetafusp and pembrolizumab
- Drug: Brenetafusp and chemotherapy
- Drug: Brenetafusp and monoclonal antibodies and chemotherapy
- Drug: Brenetafusp and tebentafusp
- Drug: Brenetafusp and bevacizumab
- Drug: Brenetafusp and kinase inhibitors
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Incidence of dose-limiting toxicity (DLT)s
measured Up to ~28 days after each dose
Phase 1: Incidence of adverse events (AE) and serious adverse events (SAE)
measured Up to 30 days after the last dose of study therapy
Phase 1: Number of participants with dose interruptions, dose reductions, or dose discontinuations
measured Up to ~12 months
Phase 1: Number of participants with abnormal laboratory test results (hematology)
measured Up to 30 days after the last dose of study therapy
Phase 1: Number of participants with abnormal laboratory test results (chemistry)
measured Up to 30 days after the last dose of study therapy
Phase 1: Number of participants with abnormal laboratory test results (coagulation)
measured Up to 30 days after the last dose of study therapy
Phase 1: Number of participants with abnormal urinalysis
measured Up to 30 days after the last dose of study therapy
Phase 1: Number of participants with abnormal vital signs
measured Up to 30 days after the last dose of study therapy
Phase 1: Mean change from baseline in QTcF interval
measured Up to 30 days after the last dose of study therapy
Phase 2: Best overall response (BOR)
measured Up to ~2 years
Permalink · IMCR's whole pipeline · Catalyst calendar · Every registered study · What changed